International audienceTo update French Society for Rheumatology recommendations about the management in clinical practice of patients with spondyloarthritis (SpA). SpA is considered across the range of clinical phenotypes (axial, peripheral, and entheseal) and concomitant manifestations. Psoriatic arthritis is included among the SpA phenotypes
AbstractThe management of spondyloarthritis is challenging and has changed with the development of n...
Therapeutic targets have been defined for axial and peripheral spondyloarthritis (SpA) in 2012, but ...
Therapeutic targets have been defined for axial and peripheral spondyloarthritis (SpA) in 2012, but ...
International audienceTo update French Society for Rheumatology recommendations about the management...
International audienceObjective: Update the French Society for Rheumatology (SFR) recommendations on...
AbstractThe management of spondyloarthritis is challenging and has changed with the development of n...
Therapeutic targets have been defined for axial and peripheral spondyloarthritis (SpA) in 2012, but ...
Therapeutic targets have been defined for axial and peripheral spondyloarthritis (SpA) in 2012, but ...
International audienceTo update French Society for Rheumatology recommendations about the management...
International audienceObjective: Update the French Society for Rheumatology (SFR) recommendations on...
AbstractThe management of spondyloarthritis is challenging and has changed with the development of n...
Therapeutic targets have been defined for axial and peripheral spondyloarthritis (SpA) in 2012, but ...
Therapeutic targets have been defined for axial and peripheral spondyloarthritis (SpA) in 2012, but ...